|
pSer129 pathology
|
|---|
| |
SNpc
|
Amyg.
|
Cing.
|
|---|
|
LBD
|
|
Case 1
|
++
|
+++
|
+++
|
|
Case 2
|
+++
|
+++
|
+++
|
|
Case 3
|
++
|
+++
|
+++
|
|
Case 4
|
+++
|
++
|
+
|
|
Case 5
|
++
|
++
|
++
|
|
Case 6
|
++
|
+
|
++
|
|
Case 7
|
+++
|
+++
|
+++
|
|
Case 8
|
+++
|
+++
|
+++
|
|
Case 9
|
++
|
++
|
++
|
|
AD/ALB
|
|
Case 15
|
–
|
−/+
|
–
|
|
Case 16
|
–
|
+
|
–
|
|
Case 17
|
−/+
|
++
|
–
|
|
Case 18
|
–
|
+++
|
–
|
|
Case 19
|
–
|
++
|
–
|
|
Case 20
|
–
|
++
|
–
|
|
Case 21
|
–
|
++
|
–
|
|
Case 22
|
–
|
+
|
–
|
|
Case 23
|
–
|
+++
|
–
|
- Following immunohistochemical staining with antibody EP1536Y and no formic acid retrieval, semi-quantitative grading was assigned to each LBD and AD/ALB case for 3 separate regions (SNpc substantia nigra pars compacta, cing. cingulate cortex, amyg. amygdala). The presence of pSer129 positive inclusions was semi-quantitatively graded at 10x magnification on a multi-tiered scale, with “-” representing non-reactivity, “−/+” very rare, “+” mild, “++” moderate, and “+++” representing the strongest level of reactivity
